The following is a summary of “Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis,” published in the January 2025 issue of Psychiatry by Fountoulakis et al.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Fact checked by Nick Blackmer The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, ...

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...

the therapy’s mechanism of action aims to address this unmet need with its nonselective, noncompetitive antagonist of the NMDA receptor. Approved in 77 countries, esketamine is indicated for ...

Ketamine-assisted therapy lifted me out of depression. But it remains costly — and controversial Health Canada approved a prescription esketamine nasal spray called Spravato in 2020 to help ...

The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few ...

Like any drug, esketamine isn’t without its risks ... Still, Spravato’s expansion into a standalone therapy means that more people with treatment-resistant depression will be able to access ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...